Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-06-10
2008-06-10
Wang, Shengjun (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252120, C514S252130, C514S252190, C514S253010, C514S253100, C514S253110
Reexamination Certificate
active
07384944
ABSTRACT:
The use of CCR5 antagonists of the formulaor a pharmaceutically acceptable salt thereof, whereinR is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl;R1is hydrogen or alkyl;R2is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl;R3is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl;R4, R5and R7are hydrogen or alkyl;R6is hydrogen, alkyl or alkenyl;for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.
REFERENCES:
patent: 5368854 (1994-11-01), Rennick
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 6037352 (2000-03-01), Lowe et al.
patent: 6066636 (2000-05-01), Kozlowski et al.
patent: WO 94/18192 (1994-08-01), None
patent: WO 96/26196 (1996-08-01), None
patent: WO 97/16440 (1997-05-01), None
patent: WO 98/05292 (1998-02-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 00/00488 (2000-01-01), None
Vandamme et al,Antiviral Chemistry and Chemotherapy, 9 (1998) p. 187-203.
Connor et al,Virology, 206 (1995) p. 935-944.
Plater-Zyberk et al,Immunol. Let., 57 (1997) p. 117-120.
Boiardi et al,Clinical and Experimental Rheumatology, 17, (1999) p. 419-425.
Hatano et al,Clin. Exp. Immunol., 117 (1999) p. 237-243.
Raychaudhuri et al,International J. of Immunopharmacology, 20 (1998) p. 661-667.
Chihara et al,J. Allergy Clin. Immunol., 100, 6, part 2 (1997) p. S52-S55.
Beck et al,J. Immunol., 159, 6 (1997) p. 2962-72.
Thea et al,J. Org. Chem., 50 (1985) p. 1867-1872.
Deng et al,Nature, 381 (1996) p. 661-666.
Dragic et al,Nature, 381 (1996) p. 667-673.
Liu et al,Cell, 86 (1996) p. 367-377.
Baroudy Bahige M.
Clader John W.
Gilbert Eric
Josien Hubert B.
Labroli Marc A.
Banerjee Krishna G.
Schering Corporation
Wang Shengjun
LandOfFree
Piperazine derivatives useful as CCR5 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives useful as CCR5 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives useful as CCR5 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797282